AZN vs GSK.L
AZN: AstraZeneca is a global pharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to address major unmet medical needs worldwide. GSK.L: A global biopharma leader specializing in vaccines and specialty medicines to address complex infectious diseases, HIV, and immune-mediated conditions.
Side-by-side fundamentals
| Metric | AZN | GSK.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $161.50 | £19.10 | |
| Market cap as of 2026-08-06 | $182.1B | n/a | |
| P/E as of 2026-08-06 | 23.47 | n/a | |
| PEG as of 2026-08-06 | 2.64 | n/a | |
| Net margin as of 2026-08-06 | +17.0% | n/a | |
| Gross margin as of 2026-08-06 | +81.3% | n/a | |
| Operating margin as of 2026-08-06 | +22.8% | n/a | |
| ROE as of 2026-08-06 | +21.7% | n/a | |
| ROA as of 2026-08-06 | +9.1% | n/a | |
| Debt / equity as of 2026-08-06 | 0.64 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +8.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.8% | n/a | |
| Dividend yield as of 2026-08-06 | +2.0% | n/a | |
| Beta as of 2026-08-06 | 1.37 | n/a | |
| 1-year return as of 2026-08-05 close | +8.4% | +36.7% | GSK.L higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.